Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 10:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 206 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: DASATINIB Clear all
Not yet recruiting Phase 1 Interventional
View directory record Official record
Conditions
HIV Infections
Interventions
Dasatinib, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Cleveland, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced May 21, 2026, 10:01 PM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dasatinib, Bortezomib, Dexamethasone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Orlando, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced May 21, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone Acetate, Prednisone, Sunitinib, Dasatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced May 21, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
Dasatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced May 21, 2026, 10:01 PM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioma
Interventions
enzyme-inducing anti-epileptic drugs
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced May 21, 2026, 10:01 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Tumors
Interventions
Dasatinib + Ketoconazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Santa Monica, California • Tampa, Florida • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced May 21, 2026, 10:01 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Dasatinib, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced May 21, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
dasatinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced May 21, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
dasatinib, pharmacological study, laboratory biomarker analysis
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced May 21, 2026, 10:01 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Squamous Cell Lung Cancer
Interventions
Dasatinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced May 21, 2026, 10:01 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Cancer
Interventions
Dasatinib, Bevacizumab, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced May 21, 2026, 10:01 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Leukemia
Interventions
Dasatinib, BMS-833923
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Hackensack, New Jersey • Nashville, Tennessee • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced May 21, 2026, 10:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Healthy
Interventions
Dasatinib + Omeprazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2009 · Synced May 21, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Leukemia, Pediatric
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Year to 17 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced May 21, 2026, 10:01 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Refractory Solid Tumors, Pancreatic Adenocarcinoma
Interventions
gemcitabine, dasatinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2015 · Synced May 21, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Dasatinib, Fulvestrant
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
28
States / cities
Sedona, Arizona • Tucson, Arizona • Hudson, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced May 21, 2026, 10:01 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Erlotinib in combination with Dasatinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced May 21, 2026, 10:01 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Aging
Interventions
Dasatinib plus Quercetin
Drug
Lead sponsor
TruDiagnostic
Industry
Eligibility
40 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced May 21, 2026, 10:01 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Squamous Cell Carcinoma Of The Head And Neck
Interventions
Cetuximab, Dasatinib
Drug
Lead sponsor
Julie E. Bauman, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced May 21, 2026, 10:01 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
Dasatinib, Leuprolide Acetate (LHRH Analogue), Radical Prostatectomy
Drug · Procedure
Lead sponsor
Noah Hahn, M.D.
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Scottsdale, Arizona • Gainesville, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced May 21, 2026, 10:01 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
dasatinib, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced May 21, 2026, 10:01 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Hematologic Malignancies, Adult
Interventions
KQB198, Dasatinib
Drug
Lead sponsor
Kumquat Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
San Francisco, California • Denver, Colorado • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced May 21, 2026, 10:01 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
dasatinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced May 21, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Pancreatic Cancer Metastatic
Interventions
Dasatinib, mFOLFOX6
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced May 21, 2026, 10:01 PM EDT